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Context: The clinical spectrum of organogenetic anomalies associated with HNF1B mutations is
heterogeneous. Besides cystic kidney disease, diabetes, and various other manifestations, odd cases
of mainly neonatal and posttransplantation cholestasis have been described. The biliary phenotype
is incompletely defined.
Objective: To systematically characterizeHNF1B-related anomalies in the bile ducts by imagingwith
magnetic resonance imaging (MRI) or magnetic resonance cholangiopancreatography (MRCP).
Setting and Patients: Fourteen patients withHNF1Bmutations in the catchment area of the Helsinki
University Hospital were evaluatedwith upper abdominalMRI andMRCP. Blood samples and clinical
history provided supplemental data on the individual phenotype.
Main OutcomeMeasure(s): Structural anomalies in the biliary system, medical history of cholestasis,
other findings in abdominal organs, diabetes and antihyperglycemic treatment, hypomagnesemia,
and hyperuricemia.
Results: Structural anomalies of the bile ducts were found in seven of 14 patients (50%). Six patients
had choledochal cysts, which are generally considered premalignant.
Conclusions: Structural anomalies of the biliary system were common in HNF1B mutation carriers.
The malignant potential of HNF1B-associated choledochal cysts warrants further studies. (J Clin
Endocrinol Metab 102: 2075–2082, 2017)
Hepatocyte nuclear factor 1B (HNF1b) is a key reg-ulator of mammalian organogenesis that is partic-
ularly required for specification of the pancreas and other
organs derived from the ventral endoderm (1–5).
Autosomal-dominantly inherited mutations in the
HNF1B gene lead to a spectrum of clinical manifesta-
tions. HNF1B mutations rank as the most common
monogenic cause of kidney and urinary tract anomalies,
with renal function ranging from normal to end-stage
renal disease (6), but kidneys can, nevertheless, appear
normal in imaging studies (7). Approximately half of
patients with HNF1B mutations develop maturity-onset
diabetes of the young (MODY) at an age ranging from
the neonatal period to adulthood, apparently as a result
of pancreatic hypoplasia and impaired insulin secretion,
in combination with hepatic insulin resistance (7–11).
The heterogeneous extrarenal manifestations also include
hypomagnesemia (12), hyperuricemia, early-onset gout
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(13, 14), genital malformations (15–17), elevated liver
enzymes (14, 18), impaired exocrine pancreatic function
(19), and increased parathyroid hormone levels with
reduced urinary calcium excretion (20). In addition,
larger microdeletions in chromosome 17q12 harboring
HNF1B result in neurologic and behavioral symptoms
(21). De novomutations occur in approximately half of
the affected persons (9).
HNF1b is involved in biliary system organogenesis,
and conditional deletion of HNF1B in mice leads to
severe jaundice, a paucity of small intrahepatic bile ducts,
and abnormalities of the gallbladder (22). In humans,
data on the possible biliary or hepatic clinical phenotype
of HNF1B disease are scarce (23–25). Seven case reports
have presented patients with either cholestasis or mainly
cholestatic liver function tests (25). A few liver biopsies in
neonateswith cholestasis showed apaucity of bile ducts and
ductal plate malformations with duct dysplasia (23–26).
Electron microscopy revealed cholangiocytes with fewer
primary cilia in biopsies from three adults whose routine
liver pathology appeared normal (27). Bile duct imaging is
rare in patients with HNF1B disease. In endoscopic ret-
rograde cholangiopancreatography (ERCP), one patient
had extrahepatic biliary atresia that was confirmed by
surgery, and on magnetic resonance imaging (MRI), one
patient had slightly dilated intra- and extrahepatic bile ducts
(25, 28). A few studies provide a limited number of patients
who have undergone abdominal MRI (11, 28). No study
has specifically focused on bile duct imaging.
Here, by use of contrast-enhanced MRI and magnetic
resonance cholangiopancreatography (MRCP), noninva-
sive imaging modalities for hepatic and pancreaticobiliary
pathologies, we report biliary abnormalities in patients with
HNF1B mutations.
Patients and Methods
In the catchment area of Helsinki University Hospital, 14
patients from the Botnia Study (www.botnia-study.org) or
the FinnMODY Study (www.botnia-study.org/finnmody) with
HNF1B mutations underwent upper abdominal MRI and
MRCP imaging as part of their clinical follow-up. The Botnia
Study has been recruiting families with diabetes from Finland
since 1990, and its extension, the FinnMODY Study, has been
recruiting patients with diagnosed or possibleMODY, aswell as
their family members, since 2014. The studies followed the
principles of the Declaration of Helsinki and were approved by
the local ethics committee, with informed consent from all study
participants.
Nine patients had awhole-allele deletion ofHNF1B, and five
patients (nos. 3, 4, 5, 6, and 13) had heterozygous intragenic
mutations. The intragenic mutations comprised a splice site
mutation in one patient, a nonsensemutation in another patient,
and nonconservative missense mutations in three patients.
Of the 14 patients (11 females, three males; age 10 to 68
years at imaging), 13 were diagnosed with diabetes at a median
age of 23 years (range, 6 to 54 years; one patient was diagnosed
during posttransplantation immunosuppressive treatment).
One remained normoglycemic at the age of 22. Eight patients
were treated with insulin, and the rest used no anti-
hyperglycemic medication (Table 1). Data for glycosylated
hemoglobin (HbA1c), serumor plasma concentration of alanine
aminotransferase (ALT), uric acid, magnesium, creatinine, and
cystatin C came from hospital records or the Botnia and
FinnMODYStudies. Glomerular filtration rate was estimated in
adults by the Chronic Kidney Disease Epidemiology Collab-
oration equation on the basis of creatinine only, and in children
by the Chronic Kidney Disease in Childhood (CKiD) Schwartz
equation on the basis of creatinine, blood urea nitrogen, and
cystatin C.
Two authors (H.P. and E.L.) interpreted the MRI scans
performed from2003 to 2016 to evaluate themorphology of the
biliary system and other abdominal organs. Cystic or fusiform
dilatations of the bile ducts [bile duct cysts (BDCs), also known
as choledochal cysts] were grouped according to the Todani
classification, if applicable (29). All scans were performed with
1.5-T whole-body scanners; gadolinium-enhanced sequences
were available in 12 and MRCP sequences in 11 patients. In
addition, genital morphology of female patients was evaluated
by MRI (nine patients), transabdominal ultrasonography (one
patient), or abdominal computed tomography scan (two pa-
tients), depending on availability. Table 1 demonstrates the
imaging summary of the patients.
The genetic testing included next-generation sequencing
confirmed with direct sequencing and/or multiplex ligation-
dependent probe amplification dosage analysis of the
HNF1B gene in two service laboratories (the Molecular Ge-
netics Laboratory in Exeter, United Kingdom, or the Genome
Center of Eastern Finland). The genetic diagnosis of one patient
with a whole-gene deletion was made through molecular kar-
yotyping analysis performed at the laboratory of the Helsinki
University Hospital.
Results
Seven of the 14 patients demonstrated bile duct anomalies
on MRI (Figs. 1–2; Table 1). Five patients had varying
types of BDCs in the extrahepatic bile ducts and gall-
bladder, whereas one patient had a 25-mm-wide
intrahepatic BDC communicating with the left main
hepatic duct (Fig. 1). In two patients (nos.12 and 14), we
observed small diverticula in the wall of the gallbladder
fundus consistent with adenomyomatosis. Patient no. 1
had undergone a BDC resection and Roux-en-Y hep-
aticojejunostomy at the age of 12 years for an incidental
BDC, and although slight widening of the proximal
intrahepatic bile ducts could be detected in the preoperative
MRI scan (Fig. 1), in the postoperative MRI scans, the
intrahepatic finding was normal (data not shown). In addi-
tion, patient no. 13 had experienced occasional episodes
of unspecific upper abdominal pain before receiving a
kidney transplantation at the age of 30, but profound
abdominal symptoms with cholestatic liver function
tests emerged after transplantation. Posttransplantation
imaging revealed moderate dilatation of extrahepatic and
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proximal intrahepatic bile ducts caused by a papillary
tumorlike mass, which by subsequent ERCP imaging and
biopsies proved to be benign adenoma.
The liver parenchyma appeared normal in all cases;
one patient had a small subcapsular cyst, which is a
common incidental finding in the general population as
well (Table 1). Nevertheless, seven patients had abnormal
serum ALT levels, which were generally less than twice
the upper reference limit. However, after major ab-
dominal surgery (patient no. 1) or renal transplantation
(patients no. 6 and 13), ALT had transiently exceeded the
upper reference limit by 24-fold.
Most patients (12 of 14) had a hypoplastic pancreas:
nine had a hypoplasia of the body and tail of the pancreas,
whereas three patients lacked only the tail (Table 1;
Fig. 3). One patient had small calcifications in the pan-
creatic parenchyma. The radiological findings did not
correlatewith the severityofdiabetes.Twopatientswithnormal
pancreas on imaging had mild diabetes without treatment
(age 10 and 27 years; HbA1c, 32 and 36 mmol/mol, re-
spectively). Of the 12 patients with hypoplastic pancre-
atic findings, the degree of glycemia varied from normal
(one 22-year-old patient had HbA1c of 35 mmol/mol) to
diabetic, and therapy ranged from none in four patients
(age 12 to 22 years; HbA1c, 33 to 44 mmol/mol) to
insulin in eight patients (age 14 to 68 years; HbA1c, 35 to
92; median HbA1c, 48 mmol/mol) (Table 1).
The pancreatic duct was of normal caliber in all pa-
tients, albeit shorter than usual in patients who had
pancreatic hypoplasia. Patient no. 12 had the normal
variant of pancreas divisum, in which the ventral and
dorsal pancreatic ducts have not fused during embryonic
development (Table 1). Patients no. 7 and 14 had small
cystic dilatations of the pancreatic branch ducts; theMRI
Table 1. Patient Clinical Characteristics and Imaging Findings




Insufficiencyb Uterus Insulin Therapy
1 12 (F) EH BDC N Tail, body Multiple cysts No Bicornuate
unicollis
Nonec
2 14 (M) N N Tail, body One cyst No — Combined
3d 10 (F) N N N Multiple cysts Milde N None
4 18 (F) EH BDC N Tail, body Multiple cysts Moderate Bicornuate
unicollis
None
5 32 (F) IH BDC N Tail, body N Moderate N Combined
6 44 (F) N N Tail Multiple cysts Severef N Intermediate-
acting
7 39 (F) EH BDC Cyst Tail, body Multiple cysts No Bicornuate
unicollis
Short-acting
8 17 (M) N N Tail, bodyg Multiple cysts in
right kidney
No — None





10 19 (F) N N Tail, body One cyst, right
kidney absent
No N Combined
11 37 (F) IH BDC N Tail, body Multiple cysts No N Combined
12 22 (M) N (gallbladderh) N Tailh Multiple cysts No — Noneh






14 68 (F) EH and IH BDCj N Tailk Multiple cysts Mild N Long-acting
Abbreviations: EH, extrahepatic; F, female; IH, intrahepatic; M, male; N, normal; NA, not available; RI, renal insufficiency.
aAt the time of MRI.
bAt the time of MRI, estimated glomerular filtration rate (millimeters per minute divided by 1.73m2): mild, 60 to 89; moderate, 30 to 59; severe, 15 to 29;
end-stage renal disease, ,15.
cLong-acting insulin started at 14 years.
dA splenic cyst.
eLater progressed to moderate.
fLater progressed to end-stage renal disease, renal transplantation.
gIntraductal papillary mucinous neoplasialike cystic dilatations of the pancreatic branch ducts.
hAdenomyomatosis of the gallbladder and pancreas divisum was observed. The horizontal duodenum did not cross the midline at its normal position,
a finding suggestive of malrotation. Normal glucose tolerance in oral glucose tolerance test.
iAfter renal transplantation, cholestatic episode caused by adenomatous tissue near ampulla of Vater.
jIn addition to the dilated biliary ducts, adenomyomatosis of the gallbladder was observed.
kA few punctate calcifications in the pancreatic parenchyma were detectable on computed tomography imaging.
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findings resembled those of intraductal papillary mu-
cinous neoplasia (Fig. 3).
With renal cysts observed in all but one patient, the
radiological findings did not correlate with the severity of
renal insufficiency; in eight of 14 (57%) patients, the
renal function appeared to be normal, whereas six pa-
tients had renal insufficiency of some degree (Table 1).
Uterine malformations were common (five of the 11 fe-
male patients) (Table 1).
Of 12 patients with data for magnesium concentra-
tions, 10 (83%) have had hypomagnesemia at some stage
of the follow-up (Fig. 4), but it was symptomatic in
only two patients (one had muscle cramps and one
had hypokalemia, despite replacement with potassium
chloride). The average (mean of individual medians)
concentration of magnesium was 0.66 mmol/L and
the lowest concentration was 0.36 mmol/L (reference
range $0.70 mmol/L). Uric acid concentration was, at
least occasionally, elevated in nine of the 14 (64%) pa-
tients, but only one had developed symptomatic gout.
The highest uric acid concentration was 1.6 times the
upper limit of normal (Fig. 4). As suggested by Clissold
Figure 1. Maximum-intensity projection images of the MRCP studies depicting the extrahepatic bile ducts and the main intrahepatic ducts for
the five patients with BDCs. All fluid is seen as white. (a) Patient no. 9, with normal extrahepatic bile ducts and gallbladder for reference. (b)
Patient no. 1, with BDC (arrow) affecting the common bile duct (type 1a by the Todani classification). The dilatation impairs bile drainage,
resulting in widened bile ducts distal to the cyst. (c) Patient no. 4, with a fusiform BDC of the common hepatic duct (arrow). The common bile
duct and the intrahepatic ducts are of normal caliber (Todani classification not applicable). (d) Patient no. 5, with an intrahepatic, 25-mm BDC
(asterisk) communicating with the left main bile duct. The debris inside the cyst is seen as dark. The biliary system was otherwise normal (Todani
classification not applicable). (e) Patient no. 7, with a fusiform BDC (width, 9 mm) of the entire extrahepatic bile ducts (asterisk) (Todani 1c). In
addition, the cystic duct (arrow) insertion to the common bile duct is abnormally low and medial (double asterisk). The intrahepatic bile ducts are
normal. (f) Patient no. 11, with multiple bile duct anomalies as well as a fusiform BDC of the common hepatic duct, similar to that of patient no. 4
(arrow). A diverticlelike BDC of the cystic duct (asterisk) and another diverticle-shaped BDC extending from the gallbladder fundus (double
asterisk) (Todani classification not applicable).
Figure 2. A schematic drawing of the (a) normal bile duct system
and (b) various anomalies we observed in our patients.
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et al. (21), patients with whole-allele deletions ofHNF1B
seemed to have lower magnesium concentrations, and
patients with intragenic mutations had higher uric acid
concentrations, but the differences were not statistically
significant (Fig. 4).
Discussion
Besides confirming the frequent occurrence of pancreatic
hypoplasia, contrast-enhanced MRI andMRCP revealed
BDCs in six of 14HNF1B carriers, which clearly exceeds
the reported 1:13,000 to 1:150,000 prevalence in West-
ern populations (30–32). Together with the develop-
mental role of HNF1B in biliary organogenesis (1, 3, 5)
and case reports on cholestasis in mutation carriers
(23–25), our report confirms a biliary phenotype in
humanHNF1B disease and shows that such a phenotype
is more prevalent than previously reported. Do these
findings have clinical implications?
In patients with HNF1B, the combination of reduced
b-cell mass (12 of the 14 patients had pancreatic hy-
poplasia), associated with functional abnormalities
in insulin secretion (10), may precipitate diabetes in non-
diabetic carriers, or worsen the hyperglycemia in di-
abetic carriers at initiation of immunosuppressive
therapy. Because many immunosuppressive agents (cal-
cineurin inhibitors, mTOR inhibitors, and steroids) in-
hibit insulin transcription and/or secretion, and steroids
decrease insulin sensitivity (33), careful monitoring of
plasma glucose after transplantation is fundamental,
irrespective of pretransplantation diabetes status of patients
with HNF1B. Not surprisingly, the two patients with a
kidney transplantation (nos. 6 and 13) showed de-
terioration of glycemic control during posttransplantation
treatment.
The multiple observations of BDCs or choledochal
cysts, which are rare cystic or fusiform dilatations of the
extrahepatic and/or intrahepatic biliary ducts, was an
unexpected finding. Yet, the pathophysiology of BDCs
is unclear. The most prevalent theory states that an
anomalous pancreaticobiliary junction (APBJ) is associ-
ated with reflux of the pancreatic juice, eventually leading
to a BDC (30–32). We did not observe an APBJ in any
patient (data not shown). Furthermore, primary stric-
tures of the common bile duct may, in part, contribute to
the dilatation of the bile ducts (32). Alternatively, BDCs
may be ductal plate malformations (34), a theory sup-
ported by reports on ductal plate malformations in some
neonatal patients with HNF1B (23–26), as well as evi-
dence in mice that inactivation of HNF1B results in such
malformations (35).
Traditionally, BDCs are classified according to the
classification system proposed by Todani et al (36), but
this has been criticized for its complexity and the need for
additions, given that not all types of cysts are covered [as
reviewed by Katabathina et al (31)]. Only three of our
patients’ BDCs had typical morphology for any Todani
class. Previously, BDCs were mostly diagnosed in chil-
dren with a triad of jaundice, abdominal pain, and
Figure 3. T2-weighted axial MRI scans of the pancreas with (a, b)
fat saturation and (c) a maximum-intensity projection image of the
MRCP images. Aplasia of the pancreatic body and tail was observed
in nine patients. One of these patients had cystic dilatations of the
pancreatic branch ducts. (a) Patient no. 9, with normal pancreas
(arrows). (b) Patient no. 7, in whom only the pancreatic head and
uncinate process can be observed (arrow). (c) Patient no. 14, with
small cystic dilatations of the pancreatic branch ducts (arrows)
consistent with branch duct intrapancreatic mucinous neoplasia. A
fusiform BDC of the extrahepatic bile ducts in their entirety (double
asterisk) and the right main bile duct (asterisk), consistent with
Todani classification type 4a, is also seen.
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palpable mass, but after advances in modern diagnostic
imaging, up to 36% of the affected are adults with in-
cidental BDCs or with nonspecific symptoms (30–32).
Indeed, excluding posttransplantation and postoperative
complications, our cohort included only one patient
with a medical history of unspecific, occasional ab-
dominal symptoms. BDCs can result in various compli-
cations, including biliary stones, cholangitis, pancreatitis,
portal hypertension, liver cirrhosis and fibrosis, as well as
spontaneous cyst ruptures. The most severe complica-
tion, however, is the risk for cholangiocarcinoma, which
increases from 0.7% in children to as high as 15% to
20% in adults (30, 37). Other malignancies (particularly
gallbladder cancer) have also been associated with
BDCs (30).
Because of their premalignant nature, the majority of
extrahepatic BDCs are surgically excised (37, 38). An
increasing number of incidental BDCs has led to a debate
as to whether only symptomatic or high-risk patients
should undergo surgery (30). Unfortunately, an indi-
vidual risk assessment is not possible. Apart from the
association between APBJs and gallbladder cancer (30),
no structural or biochemical risk factor has been iden-
tified. Is the risk of malignancy of HNF1B-related BDCs
similar to the risk of other BDCs? A previously described
patient with HNF1B and neonatal cholestasis had two
paternal family members with liver cirrhosis and liver
cancer, but information on their mutation status or the
nature of the cancer was not available (39). The frequent
finding of hypoplastic pancreas in HNF1B carriers
warrants at least careful consider-
ation of pros and cons of surgically
excising the BDCs, given that the
surgery usually includes a Roux-en-Y
hepaticojejunostomy, with partial re-
moval of the head of pancreas (37, 38),
which will potentially lead to de-
terioration of endocrine and exocrine
pancreatic functions that are already
impaired in patients with HNF1B. On
the other hand, there is no way to ac-
curately predict the individual risk of
malignancy, and the biliary anomalies
might result in technical challenges in
ERCP and increased risk for compli-
cations when collecting brush cytol-
ogy. Indeed, there were technical
problems in both of our patients who
had undergone ERCP.
In accord with previous reports of
increased levels of ALT and aspartate
aminotransferase in up to 50% to 75%
of patients with HNF1B without ap-
parent liver disease [as reviewed by Chen et al (7)], half of
our patients had slightly elevated serum ALT concen-
trations. Because liver biopsies have rarely been per-
formed and all reported patient series have been small, the
etiology remains obscure. Only two of our patients (nos.
6 and 13) were known to have had cholestatic episodes,
but in both cases, cholestasis developed after renal
transplantation and during immunosuppressive treat-
ment with calcineurin inhibitors. In vitro, calcineurin
inhibitors downregulate HNF1B gene transcription and
translation, and the downregulation of the nonmutated
allele has been associated with posttransplantation
cholestasis (28). Thus, a pretransplantation diagnosis of
HNF1B disease warrants careful follow-up of hepatic
and biliary laboratory parameters, which is crucial for
an early diagnosis of more severe forms of cholestasis.
Conclusions
Imaging with contrast-enhanced MRI and MRCP re-
vealed BDCs, also known as choledochal cysts, in six
of 14 HNF1B carriers. It is unknown whether these
choledochal cysts confer a similar risk for chol-
angiocarcinoma as BDCs in general. On the basis of this
small series of patients, recommendations for routine
screening of patients with HNF1B mutations cannot be
given. Further studies in larger patient series as well as
genetic testing of HNF1B mutations in individuals with
BDCs that have resulted in cholangiocarcinoma are
needed. In any case, surgical resection involving partial
Figure 4. The figure shows all available (a) magnesium and (b) uric acid concentrations for
the patients. A value within the reference range is shown with an open symbol, and a value
outside the reference range is shown with a filled symbol. The lower reference range for
magnesium is 0.70 mmol/L, and the upper reference limit for uric acid for adult female
patients is 350 mmol/L (the reference range for uric acid is age and sex dependent).
Magnesium values after initiation of magnesium substitution, and uric acid values after
kidney transplantation or initiation of allopurinol treatment, are excluded. Values from
patients with whole-allele deletions of HNF1B are depicted with squares, and values from
patients with intragenic mutations are depicted with with triangles.
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removal of the head of pancreas poses a significant risk for
the deterioration of insulin secretion in these patients, who
generally already lack the body and tail of the pancreas.
Finally, clinical evaluation of the other disease manifesta-
tions associated with HNF1B mutations and/or genetic
testing should be considered in patients with BDCs.
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